Achievement
SMHS is premised on holistic traditional Chinese medical views and systems biology approaches to address health issues. Research carried out in the Institute will involve and integrate data from molecules, cells, as well as studies of both structure and dynamics of interacting nodes, forming networks at multiple levels of a multidimensional matrix, including molecular, cellular, organ, person, family, community, society, and environment. We propose a holistic approach that encourages researchers, healthcare educators, Chinese medicine practitioners, clinicians and healthcare leaders to consider a more systems-based view of the individual (as an environmentally-influenced, complex biological system). When aggregated, such personal information may better explain population diversity (and population medicine), and thereby, help achieve more accurate diagnostic, efficacious therapeutic outcomes for all.
May 2022: Director of SMHS, Professor LYU Aiping was elected as a foreign member of The Academy of Europe in the field of System Medicine.
November 2022: The team lead by Director of SMHS, Professor LYU Aiping and PIs, Professor ZHANG Ge, Dr. YU yuanyuan developed a novel aptamer, which has been approved by the U.S. FDA for rare disease drug designation (RPD-2022-667) and orphan drug designation (DRU-2022-9087).
April 2023: PI of SMHS, Dr. Yu Yuanyuan wins Silver Medal at Geneva International Exhibition of Inventions.
May 2023: Collaborator of SMHS, Dr. LYU Haitao, was elected Vice Chairman of Specialty Committee on Drug Metabolism.
May 2023: PI of SMHS, Professor JIA Wei, has been rewarded the President’s Award for Outstanding Performance in Scholarly Work.
May 2023: PI of SMHS, Dr. ZHANG Lu, has been rewarded the President’s Award for Outstanding Performance in Scholarly Work.
June 2023: PI of SMHS, Professor JIA Wei, have been elected as a member of the Academia Europaea.